Cellectis SA (0WA2) AI Stock Analysis

0 Followers

Cellectis SA

(LSE:0WA2)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Allogeneic cell therapy platformCellectis is developing an allogeneic, gene-edited T-cell platform designed for off-the-shelf cancer therapies. If clinical development succeeds, this approach could support repeatable manufacturing and broader patient access, creating strategic value beyond any single candidate.

Negative Factors

Declining revenue and deep lossesThe recent revenue contraction is occurring alongside very large operating and net losses, showing that the current revenue base does not cover the company’s cost structure. Continued losses could delay break-even and keep results dependent on future development or partnership proceeds.

Cellectis SA (0WA2) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: EUR 250.97M
Dividend Yield: ―
Average Volume (3M): 2,560
Price to Earnings (P/E): -2.2
Beta (1Y): 0.34
Revenue Growth: -5.98%
EPS Growth: -8.67%
Country: UK
Employees: 227
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Cellectis SA Business Overview & Revenue Model

Company Description

Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric...

Cellectis SA Earnings Call Summary

Earnings Call Date:Aug 04, 2025(Q2-2025)|% Change Since:-54.95%|Next Earnings Date:Mar 04, 2027

Earnings Call SentimentPositive

The earnings call highlighted significant progress in advancing pivotal clinical trials and maintaining a strong financial position, with ongoing collaborations and upcoming strategic events. However, ongoing arbitration and a decrease in cash reserves posed challenges.

Positive Updates

Initiation of Pivotal Phase II Trial for lasme-cel

Cellectis is preparing to initiate the pivotal Phase II trial for lasme-cel (UCART22) in relapsed or refractory acute lymphoblastic leukemia in the second half of 2025, following successful end of Phase I discussions with the FDA and EMA.

Negative Updates

Servier Arbitration

Cellectis is engaged in arbitration with Servier regarding the termination of a licensing agreement, seeking compensation for losses due to lack of development of licensed products. The decision is expected by December 15, 2025.

Company Guidance

During Cellectis' Second Quarter 2025 Earnings Call, the company provided guidance on several key metrics. They announced the completion of end-of-Phase I discussions with the FDA and EMA for lasme-cel, UCART22, in relapsed or refractory acute lymphoblastic leukemia, and their preparation to initiate a pivotal Phase II trial in the second half of 2025. Additionally, the NatHaLi-01 study on UCART20x22 is progressing, with Phase I data anticipated by late 2025. Cellectis is advancing three cell and gene therapy programs under their partnership with AstraZeneca. Financially, the company reported cash, cash equivalents, and fixed-term deposits of $230 million as of June 30, 2025, which are expected to fund operations into the second half of 2027. They are also involved in arbitration with Servier, with a decision expected by December 15, 2025. The company will provide further insights and data during their Investor R&D Day on October 16, 2025.

Cellectis SA Risk Analysis

Cellectis SA disclosed 102 risk factors in its most recent earnings report. Cellectis SA reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Cellectis SA Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:0WA2 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FR:NANO	47Neutral	EUR 1.48B	-26.40	89.71%	―	―	―
FR:TNG	45Neutral	EUR 202.59M	-4.37	-29.36%	―	189.81%	38.50%
FR:IPH	43Neutral	EUR 154.82M	-2.60	152.56%	―	-29.48%	7.91%
FR:MAAT	38Underperform	EUR 20.18M	-0.55	―	―	-19.02%	10.39%
FR:OSE	37Underperform	EUR 40.84M	-1.01	-96.73%	―	-96.25%	-197.89%

* Healthcare Sector Average

Performance Comparison

GB:0WA2 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0WA2	Cellectis SA	1.24	-1.96	-61.28%
FR:IPH	Innate Pharma S.A.	1.33	-0.26	-16.39%
FR:NANO	Nanobiotix SA	29.04	10.86	59.74%
FR:TNG	Transgene SA	0.73	-0.54	-42.52%
FR:OSE	OSE Immunotherapeutics	1.70	-3.89	-69.55%
FR:MAAT	MaaT Pharma	1.06	-2.76	-72.25%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Cellectis SA AI Stock Analysis